Press Releases

Date Title and Summary Additional Formats
Toggle Summary Cellectar Receives FDA Fast Track Designation for CLR 131 in Diffuse Large B-Cell Lymphoma
FLORHAM PARK, N.J. , July 09, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences , Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the U.S.
View HTML
Toggle Summary Cellectar Expands Third Cohort of its Phase 2 CLOVER-1 Study of CLR 131
Response rate exceeded pre-specified value; top-line results of Phase 2 study expected in 2019 FLORHAM PARK, N.J. , May 21, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences , Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of
View HTML
Toggle Summary Cellectar Biosciences Announces Closing of $10.0 Million Financing
FLORHAM PARK, N.J. , May 20, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that it closed its previously announced
View HTML
Toggle Summary Cellectar Biosciences Announces $10.0 Million Financing
FLORHAM PARK, N.J. , May 16, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that it has entered into definitive
View HTML
Toggle Summary CLR 131 Achieves 50% Overall Response Rate in Cohort 6 of Ongoing Phase 1 Study in Relapsed or Refractory Multiple Myeloma
Results demonstrated 50% partial response rate, 50% minimal response rate, and 100% disease control rate Independent Data Monitoring Committee determines dose to be safe and well tolerated and recommends study continue to Cohort 7 FLORHAM PARK, N.J. , May 15, 2019 (GLOBE NEWSWIRE) -- Cellectar
View HTML
Toggle Summary Cellectar Receives FDA Fast Track Designation for CLR 131 in Relapsed or Refractory Multiple Myeloma
Designation could accelerate CLR 131 development and underscores the need for new treatments FLORHAM PARK, N.J. , May 13, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences , Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of
View HTML
Toggle Summary Cellectar Reports First Quarter 2019 Financial Results and Provides a Corporate Update
Reported positive top-line results from relapsed/refractory multiple myeloma cohort in ongoing Phase 2 clinical study of CLR 131 Announced median overall survival rate of 22 months in Cohorts 1-4 in its ongoing Phase 1 clinical study of CLR 131 in relapsed/refractory multiple myeloma Initiated a
View HTML
Toggle Summary FDA Grants Exemption to Import Alert for Cellectar’s CLR 131 in Pediatric and Adolescent Patients
Company to initiate Phase 1 study in pediatric and adolescent patients with select relapsed or refractory solid tumors, lymphomas and malignant brain tumors FLORHAM PARK, N.J. , March 19, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences , Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical
View HTML
Toggle Summary Cellectar Reports Financial Results for Year Ended December 31, 2018 and Provides a Corporate Update
FLORHAM PARK, N.J. , Feb. 26, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences , Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced financial results for the year ended
View HTML
Toggle Summary Cellectar Reports Positive Top-line Response Rate of 30% from R/R Multiple Myeloma Cohort in Ongoing Phase 2 Study of CLR 131
Company’s lead product candidate previously demonstrated positive top-line results from the diffuse large B-cell lymphoma cohort of this study Dosing in multiple tumor types is ongoing; Cellectar intends to report additional data this year FLORHAM PARK, N.J. , Feb.
View HTML